Abstract
Background: The urinary bladder and urethra comprise the lower urinary tracts. Pathological conditions that affect both structures necessitate reconstructive urological intervention with autologous tissue sources that cause neuromechanical and metabolic complications. Stem-cell therapies may offer an attractive alternative as they can replicate important host derived cellular functions such as mitosis, proliferation, differentiation and apoptosis.
Objective: To provide an overview on the application of stem cell therapies for regenerating the lower urinary tracts and to discuss factors that need to be addressed before stem-cells can be reliably introduced into clinical urological practice.
Results: Advantages of stem cells in reconstructive urology are their ability to self-renew and their durability. Mesenchymal stem cells (MSCs), embryonic stem cells (ESCs) and adult stem cells (ASCs) demonstrate excellent urological regenerative properties. Repairing defective lower urinary tract structures with various stem-cell derived therapies has been widely reported with encouraging results in vitro and in pre-clinical in vivo trials. Ethical considerations, cost, regulation, manufacturing and reimbursement need to be fully transparent before stem-cells are routinely applied to urological patients. International collaboration with consensus guidelines should be considered to facilitate standards that allow safe use of stem-cell therapies in urology.
Conclusion: Stem cells therapies in urology are developing rapidly with many important achievements to date. Despite promising in vitro and pre-clinical data; implementation of stem cells into daily urological practice is not imminent. Further investigation is required to determine whether stem-cells will provide better clinical outcomes than current urological tissue replacement strategies.
Keywords: Stem cells, urinary bladder, urethra, regenerative medicine, reconstructive urology, tissue engineering, urology.
Current Stem Cell Research & Therapy
Title:The Role of Stem Cells for Reconstructing the Lower Urinary Tracts
Volume: 13 Issue: 6
Author(s): Niall F. Davis*, Eoghan M. Cunnane, John J. Mulvihill, Mark R. Quinlan, Damien M. Bolton, Michael T. Walsh and Gregory S. Jack
Affiliation:
- Department of Urology, The Austin Hospital, Melbourne,Australia
Keywords: Stem cells, urinary bladder, urethra, regenerative medicine, reconstructive urology, tissue engineering, urology.
Abstract: Background: The urinary bladder and urethra comprise the lower urinary tracts. Pathological conditions that affect both structures necessitate reconstructive urological intervention with autologous tissue sources that cause neuromechanical and metabolic complications. Stem-cell therapies may offer an attractive alternative as they can replicate important host derived cellular functions such as mitosis, proliferation, differentiation and apoptosis.
Objective: To provide an overview on the application of stem cell therapies for regenerating the lower urinary tracts and to discuss factors that need to be addressed before stem-cells can be reliably introduced into clinical urological practice.
Results: Advantages of stem cells in reconstructive urology are their ability to self-renew and their durability. Mesenchymal stem cells (MSCs), embryonic stem cells (ESCs) and adult stem cells (ASCs) demonstrate excellent urological regenerative properties. Repairing defective lower urinary tract structures with various stem-cell derived therapies has been widely reported with encouraging results in vitro and in pre-clinical in vivo trials. Ethical considerations, cost, regulation, manufacturing and reimbursement need to be fully transparent before stem-cells are routinely applied to urological patients. International collaboration with consensus guidelines should be considered to facilitate standards that allow safe use of stem-cell therapies in urology.
Conclusion: Stem cells therapies in urology are developing rapidly with many important achievements to date. Despite promising in vitro and pre-clinical data; implementation of stem cells into daily urological practice is not imminent. Further investigation is required to determine whether stem-cells will provide better clinical outcomes than current urological tissue replacement strategies.
Export Options
About this article
Cite this article as:
Davis F. Niall *, Cunnane M. Eoghan, Mulvihill J. John , Quinlan R. Mark , Bolton M. Damien , Walsh T. Michael and Jack S. Gregory , The Role of Stem Cells for Reconstructing the Lower Urinary Tracts, Current Stem Cell Research & Therapy 2018; 13 (6) . https://dx.doi.org/10.2174/1574888X13666180426113907
DOI https://dx.doi.org/10.2174/1574888X13666180426113907 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracranial MR Dynamics in Clinically Diagnosed Alzheimers Disease: The Emerging Concept of “Pulse Wave Encephalopathy”
Current Alzheimer Research Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Cleft Palatal Fistula: Perspectives on Management With Review of Literature
New Emirates Medical Journal Post Dural Puncture Headache and Hypertension
Current Hypertension Reviews Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Behcets Syndrome: Literature Review
Current Rheumatology Reviews Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Pulmonary Valve Endocarditis: A Case Report
Infectious Disorders - Drug Targets Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Ultrasound Diagnosis of Soft Tissue Vascular Malformations and Tumours
Current Medical Imaging Current Management of In Situ and Invasive Cervical Adenocarcinoma
Current Women`s Health Reviews Ultrasound in Crohn’s Disease
Current Drug Targets BPC 157 and Blood Vessels
Current Pharmaceutical Design Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery Right Heart Catheterization Through Persistent Left Superior Vena Cava, an Extremely Rare Procedure and Review of Current Literature
Current Cardiology Reviews Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease
Current Pharmaceutical Design Surgical Management Options for Patients with Infertility and Endometriosis
Current Women`s Health Reviews A Review of the Management of Lymphangiomas
Current Pediatric Reviews Imaging of Abdominal Aortic Aneurysm: The Present and the Future
Current Vascular Pharmacology Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Current Vascular Pharmacology